HB Wealth Management
AKBA icon

HB Wealth Management’s Akebia Therapeutics AKBA Stock Holding History

HB Wealth Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-16,881
Closed -$19.2K – 1888
2026
Q2 		$19.2K Buy
+16,881
New +$20.1K ﹤0.01% 1702

Other funds holding AKBA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Virtus ETF Advisers
Virtus ETF Advisers New York $274M AUM 56.52% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

HB Wealth Management's AKBA Position: Q3 2026 in Review

HB Wealth Management sold out of Akebia Therapeutics (AKBA) in Q3 2026, closing a stake of 16,881 shares — an estimated $19.2K sold.

HB Wealth Management first reported a position in AKBA in Q2 2026 and held it in 1 quarter. The position peaked at $19.2K in Q2 2026. 61 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • HB Wealth Management reported no remaining Akebia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • HB Wealth Management sold 16,881 Akebia Therapeutics shares in Q3 2026, an estimated $19.2K.
  • HB Wealth Management first reported a position in Akebia Therapeutics in Q2 2026 and held it in 1 quarter.
  • HB Wealth Management's Akebia Therapeutics position peaked at $19.2K in Q2 2026.
  • 61 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on HB Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.